Form 4: Cadrenal Therapeutics Director Receives Stock Grant

Sentiment:

Insider Transaction (Form 4)


John Raymond Murphy, a Director of Cadrenal Therapeutics, Inc., received 75,000 shares of common stock on October 9, 2026.

Summary

  • Grant/award: acquired 75,000 Stock Option on October 9, 2026; holds 75,000 after (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

John Raymond Murphy — Director

DateTransactionSecuritySharesPriceValueHeld After
2026-10-09Grant/awardStock Option75,000——75,000

Key Dates

DateDescription
2026-10-09Grant/award (75,000 shares)

Keywords

insider transaction, Form 4, CVKD, Cadrenal Therapeutics, Inc., neutral, John Raymond Murphy

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.